– UK, London – Medopad, the British healthcare-tech company, announced an additional sizeable investment from Dale Ventures which increased its stake in the health-tech firm joining a host of impressive backers who’ve expressed confidence in Medopad’s ability to transform healthcare in the digital age.
Medopad has attracted the interest of Dale Wood, founder & CEO of Dale Ventures-F.Z.E alongside other leading industry investors, including pharmaceuticals giant Bayer, Hong Kong firm NWS Holdings and Chicago VC Healthbox.
“Medopad has shown tremendous growth since Dale Ventures’ initial investment and is continuing to make impressive strides toward delivering better and more personalized healthcare through the use of cutting edge biotechnology,” said Dale Wood, founder & CEO of Dale Ventures. “Medopad has the ability to transform healthcare in an exceptional way that will save time, cut expenses and change lives. I’m thrilled to be among the investors whose backing will allow for further innovation in this exciting field.”
Medopad uses advanced detection of unique biomarkers to provide remote patient monitoring through digital devices, eliminating the need for certain appointments and in-person tests.
Founders Dan Vahdat and Rich Khatib founded Medopad to transform healthcare from reactive to proactive, helping people with chronic, complex and rare diseases live fuller lives.
The personal, technology-driven healthcare sector has boomed as companies like Apple and Google invest in and develop wearable devices to track activity, heart rate, hydration levels and more. Medopad CEO Dan Vahdat took those technologies and transformed them into a cutting edge concept with limitless potential. Using noninvasive devices and tests, Medopad’s products are able to interpret the way users walk, talk and move to unlock health secrets that otherwise would rely on repetitive blood tests, frequent doctor’s visits and symptomatic analysis.
Through a smartphone application that can measure progressive symptoms of Parkinson’s or Alzheimer’s; wearable devices that can detect heart murmurs or gather information related to diabetes; and software that can relay data back to doctors and hospitals, Medopad is on the cusp of innovations that could change society’s approach to healthcare.
Dale Wood’s follow-up investment will help the company continue on its trajectory of groundbreaking innovation.
About Medopad
Medopad is a global health tech company with a mission to help people with chronic, complex, and rare diseases to live fuller lives. Medopad works with world-leading healthcare providers, pharmaceutical, insurance and technology companies, including Apple and Tencent, to build a connected digital health ecosystem. Headquartered in London, Medopad has offices in the US and China.
About Dale Ventures
Dale Ventures is a personal investment holding group founded by serial investor Dale W. Wood. The company partners with management teams to provide significant strategic and analytic resources needed to build and grow remarkable companies. Dale Ventures has adopted a consultative approach that harnesses the power of innovative teams to generate groundbreaking ideas, tactics, and strategies that drive growth and build long-term value.
For more information, visit www.Dale.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
